H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Aeon Biopharma to $5 from $6 and keeps a Buy rating on the shares. The analyst believes the outcome of the biosimilar meeting should clarify the development path for ABP-450 and should attract investor interest to provide the program’s needed funding.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEON: